Institution
Martin Luther University of Halle-Wittenberg
Education•Halle, Germany•
About: Martin Luther University of Halle-Wittenberg is a education organization based out in Halle, Germany. It is known for research contribution in the topics: Population & Liquid crystal. The organization has 20232 authors who have published 38773 publications receiving 965004 citations. The organization is also known as: MLU & University of Wittenberg.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: This article found that personal belief in a just world predicted subjective well-being and self-esteem, and this positive impact was independent of general just world belief and favorable self-perceptions.
Abstract: Differences between personal and general belief in a just world were studied in four questionnaire studies and one experiment. Personal just world belief could reliably be differentiated from general just world belief, and subjects endorsed more strongly the personal compared to the general just world belief. Moreover, personal belief in a just world predicted subjective well-being and self-esteem, and this positive impact was independent of general just world belief and favorable self-perceptions. Finally, the more subjects were aware of their own unfairness, the more the personal belief in a just world showed a negative impact on self-esteem. Results give evidence to the just world beliefs' character as world views and as indicators of a personal contract between individual and social world.
531 citations
••
TL;DR: Cancer pain management has to be embedded in a frame of palliative care, taking all the possibilities of symptom management into consideration, if pain treatment is combined with systematic symptom control.
Abstract: Most patients with advanced cancer develop diverse symptoms that can limit the efficacy of pain treatment and undermine their quality of life. The present study surveys symptom prevalence, etiology and severity in 593 cancer patients treated by a pain service. Non-opioid analgesics, opioids and adjuvants were administered following the WHO-guidelines for cancer pain relief. Other symptoms were systematically treated by appropriate adjuvant drugs. Pain and symptom severity was measured daily by patient self-assessment; the physicians of the pain service assessed symptom etiology and the severity of confusion, coma and gastrointestinal obstruction at each visit. The patients were treated for an average period of 51 days. Efficacy of pain treatment was good in 70%, satisfactory in 16% and inadequate in 14% of patients. The initial treatment caused a significant reduction in the average number of symptoms from four to three. Prevalence and severity of anorexia, impaired activity, confusion, mood changes, insomnia, constipation, dyspepsia, dyspnoea, coughing, dysphagia and urinary symptoms were significantly reduced, those of sedation, other neuropsychiatric symptoms and dry mouth were significantly increased and those of coma, vertigo, diarrhea, nausea, vomiting, intestinal obstruction, erythema, pruritus and sweating remained unchanged. The most frequent symptoms were impaired activity (74% of days), mood changes (22%), constipation (23%), nausea (23%) and dry mouth (20%). The highest severity scores were associated with impaired activity, sedation, coma, intestinal obstruction, dysphagia and urinary symptoms. Of all 23 symptoms, only constipation, erythema and dry mouth were assessed as being most frequently caused by the analgesic regimen. In conclusion, the high prevalence and severity of many symptoms in far advanced cancer can be reduced, if pain treatment is combined with systematic symptom control. Nevertheless, general, neuropsychiatric and gastrointestinal symptoms are experienced during a major part of treatment time and pain relief was inadequate in 14% of patients. Cancer pain management has to be embedded in a frame of palliative care, taking all the possibilities of symptom management into consideration.
529 citations
••
TL;DR: A pyrazolopyridine is presented that potently stimulates sGC through this site by a mechanism that is independent of NO, which results in antiplatelet activity, a strong decrease in blood pressure and an increase in survival in a low-NO rat model of hypertension, and may offer an approach for treating cardiovascular diseases.
Abstract: Nitric oxide (NO) is a widespread, potent, biological mediator that has many physiological and pathophysiological roles1. Research in the field of NO appears to have followed a straightforward path, and the findings have been progressive: NO and cyclic GMP are involved in vasodilatation; glycerol trinitrate relaxes vascular smooth muscles by bioconversion to NO; mammalian cells synthesize NO; and last, NO mediates vasodilatation by stimulating the soluble guanylate cyclase (sGC), a heterodimeric (α/β) haem protein that converts GTP to cGMP2–4. Here we report the discovery of a regulatory site on sGC. Using photoaffinity labelling, we have identified the cysteine 238 and cysteine 243 region in the α1-subunit of sGC as the target for a new type of sGC stimulator. Moreover, we present a pyrazolopyridine, BAY 41-2272, that potently stimulates sGC through this site by a mechanism that is independent of NO. This results in antiplatelet activity, a strong decrease in blood pressure and an increase in survival in a low-NO rat model of hypertension, and as such may offer an approach for treating cardiovascular diseases.
528 citations
••
30 Jun 2011TL;DR: The Functional Mockup Interface (FMI) as discussed by the authors is a tool independent standard for the exchange of dynamic models and for co-simulation, which was developed by Daimler AG within the ITEA2 project MODELISAR.
Abstract: The Functional Mockup Interface (FMI) is a tool independent standard for the exchange of dynamic models and for co-simulation. The development of FMI was initiated and organized by Daimler AG within the ITEA2 project MODELISAR. The primary goal is to support the exchange of simulation models between suppliers and OEMs even if a large variety of different tools are used. The FMI was developed in a close collaboration between simulation tool vendors and research institutes. In this article an overview about FMI is given and technical details about the solution are discussed.
528 citations
••
Case Western Reserve University1, Johns Hopkins University2, Mayo Clinic3, Harvard University4, Australian Catholic University5, University of Tennessee Health Science Center6, University of Kentucky7, University of Washington8, University of Pennsylvania9, Memorial Sloan Kettering Cancer Center10, New York Medical College11, Université de Montréal12, Martin Luther University of Halle-Wittenberg13, Centra14
TL;DR: This guideline provides timely, evidence-based reversal strategies to assist practitioners in the care of patients with antithrombotic-associated intracranial hemorrhage.
Abstract: The use of antithrombotic agents, including anticoagulants, antiplatelet agents, and thrombolytics has increased over the last decade and is expected to continue to rise. Although antithrombotic-associated intracranial hemorrhage can be devastating, rapid reversal of coagulopathy may help limit hematoma expansion and improve outcomes. The Neurocritical Care Society, in conjunction with the Society of Critical Care Medicine, organized an international, multi-institutional committee with expertise in neurocritical care, neurology, neurosurgery, stroke, hematology, hemato-pathology, emergency medicine, pharmacy, nursing, and guideline development to evaluate the literature and develop an evidence-based practice guideline. Formalized literature searches were conducted, and studies meeting the criteria established by the committee were evaluated. Utilizing the GRADE methodology, the committee developed recommendations for reversal of vitamin K antagonists, direct factor Xa antagonists, direct thrombin inhibitors, unfractionated heparin, low-molecular weight heparin, heparinoids, pentasaccharides, thrombolytics, and antiplatelet agents in the setting of intracranial hemorrhage. This guideline provides timely, evidence-based reversal strategies to assist practitioners in the care of patients with antithrombotic-associated intracranial hemorrhage.
524 citations
Authors
Showing all 20466 results
Name | H-index | Papers | Citations |
---|---|---|---|
Niels Birbaumer | 142 | 835 | 77853 |
Michael Schmitt | 134 | 2007 | 114667 |
Niels E. Skakkebæk | 127 | 596 | 59925 |
Stefan D. Anker | 117 | 415 | 104945 |
Pedro W. Crous | 115 | 809 | 51925 |
Eric Verdin | 115 | 370 | 47971 |
Bernd Nilius | 112 | 496 | 44812 |
Josep Tabernero | 111 | 803 | 68982 |
Hans-Dieter Volk | 107 | 784 | 46622 |
Dan Rujescu | 106 | 552 | 60406 |
John I. Nurnberger | 105 | 522 | 51402 |
Ulrich Gösele | 102 | 603 | 46223 |
Wolfgang J. Parak | 102 | 469 | 43307 |
Martin F. Bachmann | 100 | 415 | 34124 |
Munir Pirmohamed | 97 | 675 | 39822 |